ABSTRACT
In this chapter, we shall discuss selectively some novel therapeutic targets identified through a better understanding of tumor biology (specifically, matrix metalloproteinases, farnesyltransferase, mitogen-activated kinase, and angiogenesis). The roles of fluoropyrimidines, specific thymidylate synthase inhibitors, irinotecan, and oxaliplatin are described elsewhere in the book. This discussion of novel targets and agents that are being developed to affect these agents is not intended to be all-inclusive. As these agents progress through clinical trials, their role in the management of colorectal cancer will be defined.
